top of page


November 15, 2023

Inhalon Biopharma Secures U.S. Army Medical Research and Development Command Award to Support Development of Inhaled Therapeutics for Treatment of COVID-19  Read More

November 1, 2023

Inhalon Biopharma Expands Therapeutic Horizons with Licensing of hMPV Antibodies from the University of Georgia  Read More

October 6, 2023

Inhalon Biopharma to Share Progress in Development of Inhaled Antibody Platform at the Bio Investor Forum and Bio Europe  Read More

June 30, 2022

Inhalon Biopharma Closes Series A Financing to Further their Study of Inhaled Antibodies  Read More

October 7, 2021

Inhalon Doses First Patient in Phase 1 Study of Inhaled IN‑006 to Treat COVID-19  Read More

July 22, 2021

Inhalon Collaborates with Celltrion, Inc. to Develop Nebulized Form of Regdanvimab to Treat COVID-19 Patients at Home  Read More

July 16, 2021

Inhalon Biopharma Appoints Jeff Hutchins, Ph.D. as Chief Development Officer  Read More

May 26, 2021

Inhalon Biopharma Receives $7 Million from USAMRDC to Study Inhaled “Muco-trapping” Antibody for the Treatment of COVID-19  Read More

bottom of page